

CITATION REPORT

List of articles citing

A three-centre experience with adalimumab for the treatment of non-infectious uveitis

DOI: 10.1136/bjophthalmol-2011-301401
British Journal of Ophthalmology, 2013, 97, 134-8.

Source: <https://exaly.com/paper-pdf/56362747/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
71	Ocular vasculitis. <i>Current Rheumatology Reports</i> , 2013 , 15, 355	4.9	2
70	Treatment of chronic noninfectious uveitis in children--the trend toward tumor necrosis factor-alpha inhibition. <i>Journal of AAPOS</i> , 2013 , 17, 451-3	1.3	2
69	Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis. <i>Mediators of Inflammation</i> , 2013 , 2013, 286857	4.3	32
68	Biologic drugs in noninfectious uveitis: an update. <i>Expert Review of Ophthalmology</i> , 2013 , 8, 501-516	1.5	2
67	Current world literature. Ocular genetics. <i>Current Opinion in Ophthalmology</i> , 2013 , 24, 512-9	5.1	
66	Pharmacotherapy for uveitis: current management and emerging therapy. <i>Clinical Ophthalmology</i> , 2014 , 8, 1891-911	2.5	47
65	[Pathophysiology and new treatment of uveitis]. <i>Japanese Journal of Clinical Immunology</i> , 2014 , 37, 74-82		3
64	Adalimumab: viable treatment option for pediatric refractory uveitis?. <i>Expert Review of Ophthalmology</i> , 2014 , 9, 175-184	1.5	1
63	Adalimumab (Humira®). 2014 , 1309-1322		
62	Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study. <i>Ocular Immunology and Inflammation</i> , 2016 , 24, 319-26	2.8	24
61	Does switching anti-TNF biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 39-46	5.3	22
60	Treatment of uveitis associated with juvenile idiopathic arthritis. <i>Current Rheumatology Reports</i> , 2014 , 16, 437	4.9	16
59	Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015 , 53, 377-90	2	12
58	Recalcitrant psoriatic uveitis and anti-tumor necrosis factor- α monoclonal antibodies: experience from a psoriasis referral center. <i>International Journal of Dermatology</i> , 2015 , 54, 1105-8	1.7	4
57	The efficacy and safety of adalimumab in ocular inflammatory disease. <i>Orphan Drugs: Research and Reviews</i> , 2015 , 69		
56	The Use of Biologic Therapies in Uveitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015 , 49, 307-16	12.3	14
55	[Biologics in uveitis]. <i>Revue De Medecine Interne</i> , 2015 , 36, 107-16	0.1	6

54	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1522-30	9.5	96
53	Adalimumab in Patients with Active Noninfectious Uveitis. <i>New England Journal of Medicine</i> , 2016 , 375, 932-43	59.2	310
52	Advancements in the management of uveitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016 , 30, 304-315	5.3	23
51	Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Pediatric Rheumatology</i> , 2016 , 14, 9	3.5	26
50	Uveitis: An Update. 2016 ,		1
49	Review of the latest systemic treatments for chronic non-infectious uveitis. <i>Expert Review of Ophthalmology</i> , 2016 , 11, 111-133	1.5	2
48	Biologicals in Uveitis. 2016 , 33-42		
47	Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. <i>Clinical and Experimental Medicine</i> , 2016 , 16, 125-36	4.9	48
46	Adalimumab for Ocular Inflammation. <i>Ocular Immunology and Inflammation</i> , 2017 , 25, 405-412	2.8	30
45	Adalimumab for the treatment of non-infectious uveitis: an updated review. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 201-206	1.1	
44	Adalimumab for the treatment of uveitis. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 181-188	5.1	35
43	Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: A systematic literature review. <i>Medicine (United States)</i> , 2017 , 96, e8045	1.8	14
42	Immunosuppressive Treatment of Non-infectious Uveitis: History and Current Choices. <i>Chinese Medical Sciences Journal</i> , 2017 , 32, 48-61	1.3	9
41	Treatment recommendations for non-infectious anterior uveitis. <i>Medicina Clínica</i> , 2017 , 149, 552.e1-552.e12		8
40	Document of treatment recommendations for non-infectious anterior uveitis. <i>Medicina Clínica (English Edition)</i> , 2017 , 149, 552.e1-552.e12	0.3	
39	Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. <i>British Journal of Ophthalmology</i> , 2018 , 102, 1672-1678	5.5	18
38	Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. <i>Acta Ophthalmologica</i> , 2018 , 96, e665-e675	3.7	13
37	[Therapeutic Concepts for Treatment of Patients with Non-infectious Uveitis Biologic Disease Modifying Antirheumatic Drugs]. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2018 , 235, 553-561	0.8	1

36	Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis. <i>Ocular Immunology and Inflammation</i> , 2018 , 26, 1015-1022	2.8	3
35	Efficacy of Anti-TNF- α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients. <i>Ocular Immunology and Inflammation</i> , 2018 , 26, 477-484	2.8	17
34	Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease. <i>Ocular Immunology and Inflammation</i> , 2018 , 26, 485-489	2.8	24
33	Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation. <i>Ocular Immunology and Inflammation</i> , 2018 , 26, 1206-1211	2.8	10
32	Recommendations for the use of methotrexate in psoriatic arthritis. <i>Reumatologia Clínica</i> , 2018 , 14, 183-190		5
31	The position of biologic therapies in the treatment of non-infectious uveitis. Part I. <i>Klinika Oczna</i> , 2018 , 2018, 97-107	0.5	
30	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. <i>BioMed Research International</i> , 2018 , 2018, 9460187	3	9
29	Recommendations for the Use of Methotrexate in Psoriatic Arthritis. <i>Reumatologia Clínica (English Edition)</i> , 2018 , 14, 183-190	0.1	
28	Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 2005-2016	4.4	18
27	INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema. <i>Ocular Immunology and Inflammation</i> , 2018 , 26, 991-996	2.8	19
26	Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Medicine</i> , 2019 , 6, 104	4.9	15
25	Update in treatment of uveitic macular edema. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 667-680	4.4	22
24	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. <i>Mediators of Inflammation</i> , 2019 , 2019, 1623847	4.3	16
23	Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 43-55	5.3	43
22	Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. <i>Ophthalmology</i> , 2020 , 127, 410-416	7.3	14
21	Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioUvea) Study Group. <i>Ophthalmology</i> , 2020 , 127, 814-825	7.3	11
20	Biotherapies in Uveitis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
19	The current status of biological treatment for uveitis. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 787-811	5.1	4

18	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. <i>Inflammopharmacology</i> , 2020 , 28, 711-718	5.1	7
17	The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis. <i>Yonsei Medical Journal</i> , 2021 , 62, 177-181	3	3
16	Tolerance and efficacy of anti-TNF currently used for severe non-infectious uveitis. <i>Autoimmunity Reviews</i> , 2021 , 20, 102752	13.6	2
15	Structural Endpoints and Outcome Measures in Uveitis. <i>Ophthalmologica</i> , 2021 , 244, 465-479	3.7	2
14	Uveitis and Pregnancy. 2016 , 657-672		
13	TNF-Alpha Blocking Agents. 2016 , 293-307		2
12	Medical Therapy. 2017 , 301-316		
11	The Effect of Adalimumab on Refractory Uveitis. <i>Journal of Korean Ophthalmological Society</i> , 2020 , 61, 746-754	0.2	0
10	Vogt-koyanagi-harada syndrome in a young patient. <i>International Journal of Family & Community Medicine</i> , 2020 , 4, 92-96	0.2	
9	Subconjunctival adalimumab for treatment of dry eye disease in Sjögren's syndrome. <i>Revista Brasileira De Oftalmologia</i> , 2022 , 81,	1.8	
8	Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022 ,	2.6	1
7	Real-World outcomes of adalimumab in adults with non-infectious uveitis.. <i>Acta Ophthalmologica</i> , 2022 ,	3.7	
6	Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy.. <i>American Journal of Ophthalmology</i> , 2022 ,	4.9	0
5	Data_Sheet_1.pdf. 2019 ,		
4	Table_1.pdf. 2019 ,		
3	Table_2.pdf. 2019 ,		
2	Therapeutic Response After Immunosuppressive Drug Prescription in Non-infectious Uveitis: A Survival Analysis.		0
1	Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis. 2022 , 11, 6686		0

